Extend your learning Learn about effective ways to address problematic opioid use and overdose. DPA has an action plan that outlines a robust response focused on effective treatment, harm reduction, prevention, and… Read More
Browse Our Resources
The U.S. Food and Drug Administration (FDA) has approved three medications for use in treating opioid dependence: methadone, buprenorphine, and naltrexone. Extended release naltrexone, brand name Vivitrol®, is a… Read More
Need-to-know facts about women, prison and the drug war.
Under HAT, pharmacological heroin is administered under strict controls in a clinical setting to those who have failed in other treatments like methadone. Every published evaluation of HAT has shown extremely positive… Read More
Overview With less than 5% of the world’s population but nearly 25% of its incarcerated population, the United States imprisons more people than any other nation in the world – largely due to the war on drugs.… Read More
This fact sheet explains how 911 Good Samaritan laws can save lives. These laws protect people from arrest and prosecution for drug possession when they call 911 to report an overdose.
List of states with 911 Good Samaritan laws and/or naloxone access policies in place.
What Television Can and Can't Tell Us About Women, The Drug War, and Mass Incarceration: A Talk with Piper Kerman and DPA's asha bandele
In the Drug Policy Alliance’s third installment of its 2015 Telephone Town Hall series, which is designed to expand the breadth and depth of those concerned with ending the drug war, the organization’s… Read More
Watch the recording now! Harm reduction services and syringe exchange are more than just a prevention strategy. Access to these vital services enables HIV testing, linkage to care and other critical health/social… Read More
Statement of Support
On April 7, 2015, Ethan Nadelmann, Executive Director of the Drug Policy Alliance, presented oral testimony in support of sections 11-20 of SB275 at a hearing of the Nevada State Senate Revenue and Economic Development… Read More